Antibody-Drug Conjugates

View All

Delveinsight
Antibody-Drug Conjugate and Big Pharmaceutical Companies

Antibody Drug Conjugate and Big Pharmaceutical Companies Boom Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the d...

Find More

Delveinsight
Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis

Antibody-Drug Conjugates-A Big Boom! Therapeutics developed to create innovative medicines based on the use of new and improved antibodies is the next generation cure for the treatment of various diseases. In past decade, the antibody drug conjugates have emerged out as the active areas of many biopharmaceutical ...

Find More

Delveinsight
Antibody-Drug Conjugates Market Outlook, 2015 Report

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the ch...

Find More

Delveinsight
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...

Find More